Deck Bio

Deck Bio is a private biotechnology company developing next-generation T cell engager immunotherapies for solid tumors. Its approach focuses on tumor-exclusive peptide-major histocompatibility complex targets, aiming to access intracellular cancer antigens that are not reachable with conventional biologics. The company is building a multi-target platform intended to address tumor heterogeneity, antigen escape, and resistance while improving patient coverage and durability of response. Deck Bio's technology stack includes T cell receptor specificity engineering, stabilized T cell receptor binding domains, and modular T cell engager design. Its lead disclosed program, DBXO-1, is in preclinical development.